Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
ERBB2 Gene Amplification: early-phase trial registry
1 of 3 indexed ERBB2 Gene Amplification trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #5,209 of 28,707 conditions by registered trial count.
3 US clinical trials · 1 currently recruiting · #5,209 of 28,707 conditions by registered trial count
ERBB2 Gene Amplification: 3 US clinical trials tracked, 1 recruiting.
ERBB2 Gene Amplification is the subject of 3 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most active sponsor is Cogent Biosciences, running 1 of these trials.
Enrollment posture brief
Registry condition erbb2-gene-amplification
OPEN 1 | RECR 33% | LATE 0 | EARLY 3 | RANK #5209 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Adherence, Treatment (33% recruiting · 6 trials)
ERBB2 Gene Amplification lists 1 open slots (33% of 3 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for ERBB2 Gene Amplification on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
ERBB2 Gene Amplification is recruiting below its size-band peers.
1 of 3 indexed trials (33.3%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
3 total, page 1 of 1
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
Cogent Biosciences
NCT07361562
Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation
M.D. Anderson Cancer Center
NCT03065387
Trastuzumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer
National Cancer Institute (NCI)
NCT00006089
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on ERBB2 Gene Amplification records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on ERBB2 Gene Amplification trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this ERBB2 Gene Amplification page
3 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 ERBB2 Gene Amplification trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Cogent Biosciences sponsors the most ERBB2 Gene Amplification trials on record, review their full trial history before evaluating a specific study. See Cogent Biosciences's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This ERBB2 Gene Amplification condition card totals 3 registered trials; most-linked intervention Trastuzumab; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.